Oncology Medical News about metastatic medullary thyroid cancer;Motesanib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Journal of Clinical Oncology, 07/08/09

Schlumberger MJ et al. - In a trial to investigate the efficacy and tolerability of motesanib, platelet-derived growth factor receptor, and Kit in advanced medullary thyroid cancer (MTC), it was reported that although objective response rate was low, a significant proportion of MTC pts (81%) achieved stable disease while receiving motesanib.

Methods

Pts with locally advanced or metastatic, progressive or symptomatic MTC received motesanib 125 mg/d orally for up to 48 wks or until unacceptable toxicity or disease progression.
Primary endpoint was objective response by independent review.
Other endpoints included duration of response, progression-free survival (PFS), safety, pharmacokinetics, and changes in tumor markers.

Results

Of 91 enrolled pts who received motesanib, 2 (2%) achieved objective response; their duration of response was 32 wks (censored) and 21 wks (disease progressed).
81% of pts had stable disease (48% had durable stable disease ≥24 wks), 8% had disease progression as best response, and 9% were not evaluated; 76% experienced a decrease from baseline in target lesion measurement.
Median PFS was 48 wks.
Among pts with tumor marker analysis, 69 (83%) of 83 and 63 (75%) of 84 had decreased serum calcitonin and carcinoembryonic antigen during treatment, respectively, compared with baseline.
Most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%).
In pharmacokinetic analyses, motesanib trough concentrations were lower compared with differentiated thyroid cancer pts from the same study.

<< Previous
Intensity-modulated radiation therapy with or without...

Next >>
Insulin resistance and risk factors for cardiovascular disease in...

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 10/30/09 Relevance Score: 82%

Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer
Cancer, 11/12/09 Relevance Score: 81%

Adult onset Stills disease diagnosed concomitantly with occult papillary thyroid cancer: paraneoplastic manifestation or coincidence
Clinical Rheumatology, 11/12/09 Relevance Score: 79%

Outcome after thyroid surgery for metastasis from renal cell cancer
Surgery, 11/03/09 Relevance Score: 79%

Medullary thyroid cancer: RET testing of an archival material
European Archives of Oto-Rhino-Laryngology, 10/21/09 Relevance Score: 79%